[Tranylcypromine for chronic therapy-resistant agoraphobia with panic disorder and recurrent depressive disorder].
OBJECTIVE
Tranylcypromine has been recommend as an option for therapy-resistant depressive and anxiety disorders. In this case report the effectiveness of this medication as a part of a combined therapy-program including pharmacological, behavioural and psychodynamic interventions could be demonstrated on an outpatient with a therapy-resistant depression and agoraphobia.


METHODS
The development of the illness, clinical symptoms and the 4 year ongoing therapy of a 69-year old patient are described in detail.


CONCLUSIONS
After the failure of 13 antidepressant agents with considerable side effects, a one year sustained remission of depression as well as great improvement of agoraphobia could be achieved with tranylcypromine. In this situation, tranylcypromine showed itself, for the first time, to be a very effective and well tolerated antidepressant.
Boerner
Reinhard J
RJ
Zentrum für Psychologische und Psychosoziale Medizin, Christliches Krankenhaus Quakenbrück GmbH, Akademisches Lehrkrankenhaus der MHH, Quakenbrück. r.boerner@ckq-gmbh.de
Lühring
Frauke
F
D000368:Aged; D000379:Agoraphobia / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D000553:Ambulatory Care; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000627:therapeutic use*; D015928:Cognitive Behavioral Therapy; D003131:Combined Modality Therapy; D015897:Comorbidity; D003865:Major Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D004351:Drug Resistance; D005500:Follow-Up Studies; D006801:Humans; D007171:Implosive Therapy; D008297:Male; D016584:Panic Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D010359:Patient Readmission; D011575:Psychoanalytic Therapy; D014191:Tranylcypromine / Q000627:therapeutic use*; D016896:Treatment Outcome
D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D014191:Tranylcypromine